Guideline / position statementindependent cross-checkabstract only checked I-GUT-05 standard review
ACG IBS guideline
ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
Overview
Lacy BE et al.. Am J Gastroenterol 2021 · PMID 33315591 · DOI 10.14309/ajg.0000000000001036
A low-FODMAP diet trial is recommended, along with drugs and psychotherapy.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
IBS management.
- How was the study done?
Guideline.
- What was actually found?
Multiple therapies.
- What do the results mean in everyday life?
Diet helps some.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Applicable.
Scientific in-depth review
1. Full reference
- Authors
- Lacy BE et al.
- Journal
- Am J Gastroenterol
- Year
- 2021
- Identifier
- PMID 33315591 DOI 10.14309/ajg.0000000000001036
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Management of IBS
3. Study design and population
- Study design
- Guideline / position statement – Clinical guideline (ACG), GRADE
- Population
Patients with IBS
- Country
USA
- Period
2021
4. Methods and endpoints
- Exposure / intervention
Diagnostics and therapies
- Endpoints
Recommendations
- Statistical methods
GRADE; modified Delphi
5. Actual results
- Results
Recommend a limited trial of a low-FODMAP diet; rule out coeliac disease (diarrhoea) and IBD (calprotectin); recommend chloride channel and guanylate cyclase activators (IBS-C), rifaximin (IBS-D); suggest gut-directed psychotherapy.
- Absolute risks
not applicable
- Authors' conclusion
First ACG IBS guideline with GRADE-based recommendations.
6. Strengths
- GRADE
7. Weaknesses
- Abstract only
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline.
9. Assessment of the statistical interpretation
10. Relevance to the specific claim
C-GUT-01, -02.
11. Independent contrary findings
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Diet is one evidence-based option among several.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- Reflux (heartburn) and irritable bowel syndrome are largely driven by eating habits; removing white/baladi bread, baked goods and soft drinks can improve symptoms. – Studies supporting the claim
- Stopping bread and baked goods for five days will improve 85% of reflux and IBS symptoms within at most ten days; both diseases can be eliminated completely. – Studies contradicting or limiting the claim